Literature DB >> 20480531

Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer.

Rui-Qing Peng1, Ying-Bo Chen, Ya Ding, Rong Zhang, Xing Zhang, Xing-Juan Yu, Zhi-Wei Zhou, Yi-Xin Zeng, Xiao-Shi Zhang.   

Abstract

AIM: To investigate the correlation between expression of calreticulin and infiltration of lymphocytes in stage IIIB colon cancer.
METHODS: Sixty-eight pathologically-confirmed specimens were obtained from stage IIIB (T3N1M0) colon cancer patients who underwent radical resection between January 1999 and May 2002 at the Cancer Center of Sun Yat-Sen University, Guangzhou, China. Immunohistochemical analysis was performed to show infiltration of lymphocytes and expression of calreticulin in colon cancer. Association between calreticulin expression, infiltration of lymphocytes, and 5-year survival rate of patients was assessed.
RESULTS: The expression level of calreticulin was lower in cancer nest than in its adjacent normal epithelium since 61.8% (42/68) of the samples were stained with calreticulin in colon cancer. The expression of calreticulin in colon cancer was associated with the infiltration of CD45RO+ cells rather than with that of CD3+ cells. In addition, the stronger expression of calreticulin and the higher infiltration of CD3+ and CD45RO+ cells in colon cancer were associated with the higher 5-year survival rate of patients.
CONCLUSION: Expression of calreticulin is associated with infiltration of T-cells, which implies that a low expression level of molecular marker may represent a new mechanism underlying immune escape in colon cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20480531      PMCID: PMC2874150          DOI: 10.3748/wjg.v16.i19.2428

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  44 in total

1.  Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer.

Authors:  K M Ropponen; M J Eskelinen; P K Lipponen; E Alhava; V M Kosma
Journal:  J Pathol       Date:  1997-07       Impact factor: 7.996

2.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue].

Authors:  W Remmele; H E Stegner
Journal:  Pathologe       Date:  1987-05       Impact factor: 1.011

3.  Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases.

Authors:  Johannes Hansler; Thaddaus-Till Wissniowski; Detlef Schuppan; Astrid Witte; Thomas Bernatik; Eckhart-Georg Hahn; Deike Strobel
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

4.  Roles of calreticulin and calnexin during mucin synthesis in LS180 and HT29/A1 human colonic adenocarcinoma cells.

Authors:  D J McCool; Y Okada; J F Forstner; G G Forstner
Journal:  Biochem J       Date:  1999-08-01       Impact factor: 3.857

5.  Morphological observation of tumor infiltrating immunocytes in human rectal cancer.

Authors:  Zun-Jiang Xie; Li-Min Jia; Ye-Chun He; Jiang-Tao Gao
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

6.  Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.

Authors:  Pierpaolo Correale; Maria Grazia Cusi; Kwong Yok Tsang; Maria Teresa Del Vecchio; Stefania Marsili; Marco La Placa; Chiara Intrivici; Angelo Aquino; Lucia Micheli; Cristina Nencini; Francesco Ferrari; Giorgio Giorgi; Enzo Bonmassar; Guido Francini
Journal:  J Clin Oncol       Date:  2005-08-01       Impact factor: 44.544

Review 7.  Calreticulin, a Ca2+-binding chaperone of the endoplasmic reticulum.

Authors:  Pascal Gelebart; Michal Opas; Marek Michalak
Journal:  Int J Biochem Cell Biol       Date:  2005-02       Impact factor: 5.085

8.  An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer.

Authors:  Su-Hyung Hong; David E Misek; Hong Wang; Eric Puravs; Thomas J Giordano; Joel K Greenson; Dean E Brenner; Diane M Simeone; Craig D Logsdon; Samir M Hanash
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

Review 9.  Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation.

Authors:  Abhishek D Garg; Dominika Nowis; Jakub Golab; Peter Vandenabeele; Dmitri V Krysko; Patrizia Agostinis
Journal:  Biochim Biophys Acta       Date:  2009-08-28

10.  Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth.

Authors:  S E Pike; L Yao; K D Jones; B Cherney; E Appella; K Sakaguchi; H Nakhasi; J Teruya-Feldstein; P Wirth; G Gupta; G Tosato
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

View more
  36 in total

1.  Tumor-infiltrating memory T-lymphocytes for prognostic prediction in cancer patients: a meta-analysis.

Authors:  Qingzhu Jia; Yi Yang; Ying Wan
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysis.

Authors:  Abhishek D Garg; Dirk De Ruysscher; Patrizia Agostinis
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

Review 3.  Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation.

Authors:  A D Garg; E Romano; N Rufo; P Agostinis
Journal:  Cell Death Differ       Date:  2016-02-19       Impact factor: 15.828

4.  Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy.

Authors:  Heng Yang; Yuting Ma; Guo Chen; Heng Zhou; Takahiro Yamazaki; Christophe Klein; Federico Pietrocola; Erika Vacchelli; Sylvie Souquere; Allan Sauvat; Laurence Zitvogel; Oliver Kepp; Guido Kroemer
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

5.  Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate.

Authors:  Sylvain Ladoire; Laura Senovilla; David Enot; François Ghiringhelli; Vichnou Poirier-Colame; Kariman Chaba; Gulsun Erdag; Jochen T Schaefer; Donna H Deacon; Laurence Zitvogel; Craig L Slingluff; Guido Kroemer
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

Review 6.  The Course of Immune Stimulation by Photodynamic Therapy: Bridging Fundamentals of Photochemically Induced Immunogenic Cell Death to the Enrichment of T-Cell Repertoire.

Authors:  Shubhankar Nath; Girgis Obaid; Tayyaba Hasan
Journal:  Photochem Photobiol       Date:  2019-11-10       Impact factor: 3.421

Review 7.  Immune parameters affecting the efficacy of chemotherapeutic regimens.

Authors:  Laurence Zitvogel; Oliver Kepp; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2011-03       Impact factor: 66.675

Review 8.  Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers.

Authors:  Vanessa Acebes-Fernández; Alicia Landeria-Viñuela; Pablo Juanes-Velasco; Angela-Patricia Hernández; Andrea Otazo-Perez; Raúl Manzano-Román; Rafael Gongora; Manuel Fuentes
Journal:  Nanomaterials (Basel)       Date:  2020-06-29       Impact factor: 5.076

9.  Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer.

Authors:  Gautier Stoll; Kristina Iribarren; Judith Michels; Alexandra Leary; Laurence Zitvogel; Isabelle Cremer; Guido Kroemer
Journal:  Oncoimmunology       Date:  2016-06-09       Impact factor: 8.110

10.  Primary glioblastoma multiforme tumors and recurrence : Comparative analysis of the danger signals HMGB1, HSP70, and calreticulin.

Authors:  Carolin Muth; Yvonne Rubner; Sabine Semrau; Paul-Friedrich Rühle; Benjamin Frey; Annedore Strnad; Rolf Buslei; Rainer Fietkau; Udo S Gaipl
Journal:  Strahlenther Onkol       Date:  2015-12-08       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.